• Skip to primary navigation
  • Skip to content

Resource Tracking Working Group

Investment priorities to fund innovation in a challenging global landscape

  • Findings
  • Investment by Prevention Option
    • AIDS Vaccines
    • Microbicides
    • Cure and Therapeutic Vaccines
    • Pre-Exposure Prophylaxis
    • Treatment as Prevention
    • Female Condoms
    • Voluntary Medical Male Circumcision
    • Prevention of Vertical Transmission
  • Graphics
  • Archive

Prevention of Vertical Transmission

Funding for PMTCT increased by one percent, with levels rising from US$35.7 million to US$36 million in 2018 (Table 7). The number of donors financing PMTCT research also increased from seven to 12 in 2018. Most PMTCT research (almost 97 percent) was funded by the public sector, with the US NIH remaining the largest donor, at US$31 million. European funding increased by 477 percent, which can be attributed largely to commitments from the EDCTP (US$2.1 million) and the European Commission (US$0.1 million). Philanthropic funding levels also rose to US$1.03 million, bolstered by funding from BMGF, Wellcome Trust and Aidsfonds.

Annual Investment in Prevention of Vertical Transmission by Sector

For more, read the full report.

© 2000–2021 HIV Resource Tracking
(Privacy Policy)